Complete loss of EPCAM immunoexpression identifies EPCAM deletion carriers in MSH2-negative colorectal neoplasia
Autor/a
Cuatrecasas, Míriam
Gorostiaga, Iñigo
Riera, Cristina
Saperas, Esteban
Llort, Gemma
Costa, Irmgard
Matias-Guiu, Xavier
Carrato, Cristina
Navarro, Matilde
Pineda, Marta
Dueñas, Núria
Brunet, Joan
Marco, Vicente
Trias, Isabel
Busteros, José Ignacio
Mateu, Gemma
Balaguer, Francesc
Fernández-Figueras, María-Teresa
Musulén, Eva
Fecha de publicación
2020ISSN
2072-6694
Resumen
The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to MSH2 alterations. LS was confirmed in 68 patients, 53 with MSH2 mutations and 15 with EPCAM 3′-end deletions. Tissue microarrays were constructed with human normal tissues and their malignant counterparts to assist in the evaluation of EPCAM staining. Among 154 MSH2-negative lesions, 17 were EPCAM-negative, including 10 CRC and 7 colorectal polyps, and 5 of them showed only isolated negative glands. All lesions showing a lack of EPCAM expression belonged to patients with EPCAM 3′-end deletions. EPCAM IHC is a useful screening tool, with 100% specificity to identify LS patients due to EPCAM 3′-end deletions in MSH2-negative CRC and MSH2-negative colorectal polyps. View Full-Text
Tipo de documento
Artículo
Versión del documento
Versión publicada
Lengua
English
Materias (CDU)
61 - Medicina
616 - Patología. Medicina clínica. Oncología
Palabras clave
Còlon -- Càncer
Immunohistoquímica
Pòlips (Patologia)
Tumors
Mutació (Biologia)
Colon -- Cáncer
Inmunohistoquímica
Pólipos (Patología)
Tumores
Mutación (Biología)
Colon cancer
Immunohistochemistry
Polyps (Pathology)
Tumors
Mutation (Biology)
Páginas
20
Publicado por
MDPI
Colección
12; 10
Publicado en
MDPI
Citación
Cuatrecasas, Míriam; Gorostiaga, Iñigo; Riera, Cristina [et al.]. Complete loss of EPCAM immunoexpression identifies EPCAM deletion carriers in MSH2-negative colorectal neoplasia. Cancers, 2020, 12(10), p. 1-20. Disponible en: <https://www.mdpi.com/2072-6694/12/10/2803>. Fecha de acceso: 3 nov. 2020. DOI: 10.3390/cancers12102803
Este ítem aparece en la(s) siguiente(s) colección(ones)
- Ciències de la Salut [740]
Derechos
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by/4.0/